Background Allergen immunotherapy (AIT) is the only disease-modifying treatment in patients with seasonal allergic rhinoconjunctivitis (SAR). Its efficacy depends on the precise identification of the triggering allergen. However, diagnostics based on retrospective clinical history and sensitization to whole extracts (SWE) often leads to equivocal results.Objectives To assess the usability and impact of a recently established algorithm for a clinical decision support system (@IT2020-CDSS) for SAR and its diagnostic steps [anamnesis, SWE (skin prick test or serum IgE), component resolved diagnosis, CRD, and real-time digital symptom recording, eDiary] on doctor's AIT prescription decisions.Methods After educational training on the @IT2020-CDS...
International audienceThe European Academy of Allergy and Clinical Immunology (EAACI) is in the proc...
BACKGROUND: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of dev...
International audienceThe European Academy of Allergy and Clinical Immunology (EAACI) is in the proc...
Background Allergen immunotherapy (AIT) is the only disease-modifying treatment in patients with sea...
Background Allergen immunotherapy (AIT) is the only disease-modifying treatment in patients with sea...
Background Allergen immunotherapy (AIT) is the only disease-modifying treatment in patients with sea...
Background: Allergen immunotherapy (AIT) is the only disease-modifying treatment in patients with se...
Allergic rhinoconjunctivitis (ARC) is one of the commonest chronic diseases worldwide with increasin...
Allergic rhinitis (AR) is very commonly caused by pollens. The symptoms of AR consist of sneezing, n...
Allergen immunotherapy (AIT) reduces symptoms and medication use associated with allergic rhinitis w...
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of dev...
Background: Allergen immunotherapy (AIT) has been thoroughly documented in randomized controlled tri...
The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the ...
International audienceAllergen immunotherapy (AIT) reduces symptoms and medication use associated wi...
International audienceThe European Academy of Allergy and Clinical Immunology (EAACI) is in the proc...
International audienceThe European Academy of Allergy and Clinical Immunology (EAACI) is in the proc...
BACKGROUND: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of dev...
International audienceThe European Academy of Allergy and Clinical Immunology (EAACI) is in the proc...
Background Allergen immunotherapy (AIT) is the only disease-modifying treatment in patients with sea...
Background Allergen immunotherapy (AIT) is the only disease-modifying treatment in patients with sea...
Background Allergen immunotherapy (AIT) is the only disease-modifying treatment in patients with sea...
Background: Allergen immunotherapy (AIT) is the only disease-modifying treatment in patients with se...
Allergic rhinoconjunctivitis (ARC) is one of the commonest chronic diseases worldwide with increasin...
Allergic rhinitis (AR) is very commonly caused by pollens. The symptoms of AR consist of sneezing, n...
Allergen immunotherapy (AIT) reduces symptoms and medication use associated with allergic rhinitis w...
Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of dev...
Background: Allergen immunotherapy (AIT) has been thoroughly documented in randomized controlled tri...
The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the ...
International audienceAllergen immunotherapy (AIT) reduces symptoms and medication use associated wi...
International audienceThe European Academy of Allergy and Clinical Immunology (EAACI) is in the proc...
International audienceThe European Academy of Allergy and Clinical Immunology (EAACI) is in the proc...
BACKGROUND: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of dev...
International audienceThe European Academy of Allergy and Clinical Immunology (EAACI) is in the proc...